cGMP signaling, phosphodiesterases and major depressive disorder

Current Neuropharmacology

Volumn 9, Issue 4, 2011, Pages 715-727

  Reierson, Gillian W ^a   Guo, Shuyu ^b   Mastronardi, Claudio ^b   Licinio, Julio ^b   Wong, Ma Li ^b  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b Australian National University   (Australia)

Author keywords

Antidepressants; Cyclases; Cyclic guanosine monophosphate; Major Depression; Neurogenesis; Neuroplasticity; Pharmacology; Phophodiesterases

Indexed keywords

2 [1 (2 FLUOROBENZYL) 1H PYRAZOLO[3,4 B]PYRIDIN 3 YL] 5 MORPHOLINO 4,6 PYRIMIDINEDIAMINE; 4 AMINO 5 CYCLOPROPYL 2 [1 (2 FLUOROBENZYL) 1H PYRAZOLO[3,4 B]PYRIDIN 3 YL]PYRIMIDINE; 7 NITROINDAZOLE; ADENOSINE; AMFEBUTAMONE; AMRINONE; ANAGRELIDE; ARGININE; ATROPINE; BAY 607550; CILOSTAZOL; CINACIGUAT; CITALOPRAM; CYCLIC AMP; CYCLIC GMP; FLUOXETINE; IMIDAZOLE; IMIPRAMINE; METHYLENE BLUE; MILRINONE; N(G) NITROARGININE METHYL ESTER; ND 7001; NITRIC OXIDE SYNTHASE INHIBITOR; PHOSPHODIESTERASE; PHOSPHODIESTERASE INHIBITOR; POSTSYNAPTIC RECEPTOR; RIOCIGUAT; SEROTONIN TRANSPORTER; SILDENAFIL; TADALAFIL; TIANEPTINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VARDENAFIL; VENLAFAXINE;

ACUTE HEART FAILURE; CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION; DOWNSTREAM PROCESSING; DRUG EFFECT; DRUG MEGADOSE; ENZYME ACTIVITY; GENE EXPRESSION; GENOTYPE; LEARNING; MAJOR DEPRESSION; MEMORY; NERVE CELL; NERVE CELL PLASTICITY; NERVOUS SYSTEM DEVELOPMENT; NONHUMAN; PHENOTYPE; PROTEIN FUNCTION; PROTEIN SYNTHESIS REGULATION; PULMONARY HYPERTENSION; REVIEW; SIGNAL TRANSDUCTION;

EID: 82955192554     PISSN: 1570159X     EISSN: 18756190     Source Type: Journal    
DOI: 10.2174/157015911798376271     Document Type: Review

References (130)

1. Blazer, D.G., Kessler, R.C., Swartz, M.S. Epidemiology of recurrent major and minor depression with a seasonal pattern. The National comorbidity survey. Br. J. Psychiatry, 1998, 172, 164-167.
2. Wong, M.L., Licinio, J. From monoamines to genomic targets: a paradigm shift for drug discovery in depression. Nat. Rev. Drug, 2004, Discov., 3, 136-151.
3. Duman, R.S., Monteggia, L.M. A neurotrophic model for stressrelated mood disorders. Biol. Psychiatry, 2006, 59, 1116-1127.
4. Duman, C.H., Schlesinger, L., Russell, D.S., Duman, R.S. Voluntary exercise produces antidepressant and anxiolytic behavioral effects in mice. Brain Res., 2008, 1199, 148-158.
5. Chen, C.C., Yang, C.H., Huang, C.C., Hsu, K.S. Acute stress impairs hippocampal mossy fiber-CA3 long-term potentiation by enhancing cAMP-specific phosphodiesterase 4 activity. Neuropsychopharmacology, 2010, 35, 1605-1617.
6. Bartsch, D., Casadio, A., Karl, K.A., Serodio, P., Kandel, E.R. CREB1 encodes a nuclear activator, a repressor, and a cytoplasmic modulator that form a regulatory unit critical for long-term facilitation. Cell, 1998, 95, 211-223.
7. Conti, A.C., Cryan, J.F., Dalvi, A., Lucki, I., Blendy, J.A. cAMP response element-binding protein is essential for the upregulation of brain-derived neurotrophic factor transcription, but not the behavioral or endocrine responses to antidepressant drugs. J. Neurosci., 2002, 22, 3262-3268.
8. Dhir, A., Kulkarni, S.K. Effect of addition of yohimbine (alpha-2 receptor antagonist) to the antidepressant activity of fluoxetine or venlafaxine in the mouse forced swim test. Pharmacology, 2007, 80, 239-243.
9. Feil, S., Zimmermann, P., Knorn, A., Brummer, S., Schlossmann, J., Hofmann, F., Feil, R. Distribution of cGMP-dependent protein kinase type I and its isoforms in the mouse brain and retina. Neuroscience, 2005, 135, 863-868.
10. de Vente, J., Asan, E., Gambaryan, S., Markerink-van Ittersum, M., Axer, H., Gallatz, K., Lohmann, S.M., Palkovits, M. Localization of cGMP-dependent protein kinase type II in rat brain. Neuroscience, 2001, 108, 27-49.
11. Dhir, A., Kulkarni, S.K. Involvement of L-arginine-nitric oxidecyclic guanosine monophosphate pathway in the antidepressantlike effect of venlafaxine in mice. Prog. Neuropsychopharmacol. Biol. Psychiatry, 2007, 31, 921-925.
12. Knowles, R.G., Palacios, M., Palmer, R.M., Moncada, S. Formation of nitric oxide from L-arginine in the central nervous system: a transduction mechanism for stimulation of the soluble guanylate cyclase. Proc. Natl. Acad. Sci. U. S. A., 1989, 86, 5159-5162.
13. Bredt, D.S., Snyder, S.H. Nitric oxide mediates glutamate-linked enhancement of cGMP levels in the cerebellum. Proc. Natl. Acad. Sci. U. S. A, 1989, 86, 9030-9033.
14. Fesenko, E.E., Kolesnikov, S.S., Lyubarsky, A.L. Induction by cyclic GMP of cationic conductance in plasma membrane of retinal rod outer segment. Nature, 1985, 313, 310-313.
15. Schlegel, P.A., Jen, P.H., Singh, S. Auditory spatial sensitivity of inferior collicular neurons of echolocating bats. Brain Res., 1988, 456, 127-138.
16. Leinders-Zufall, T., Cockerham, R.E., Michalakis, S., Biel, M., Garbers, D.L., Reed, R.R., Zufall, F., Munger, S.D. Contribution of the receptor guanylyl cyclase GC-D to chemosensory function in the olfactory epithelium. Proc. Natl. Acad. Sci. U. S. A., 2007, 104, 14507-14512.
17. Lowe, D.G., Dizhoor, A.M., Liu, K., Gu, Q., Spencer, M., Laura, R., Lu, L., Hurley, J.B. Cloning and expression of a second photoreceptor-specific membrane retina guanylyl cyclase (RetGC), RetGC-2. Proc. Natl. Acad. Sci. U. S. A., 1995, 92, 5535-5539.
18. Shyjan, A.W., de Sauvage, F.J., Gillett, N.A., Goeddel, D.V., Lowe, D.G. Molecular cloning of a retina-specific membrane guanylyl cyclase. Neuron, 1992, 9, 727-737.
19. Yang, R.B., Robinson, S.W., Xiong, W.H., Yau, K.W., Birch, D.G., Garbers, D.L. Disruption of a retinal guanylyl cyclase gene leads to cone-specific dystrophy and paradoxical rod behavior. J. Neurosci., 1999, 19, 5889-5897.
20. Langub, M.C., Jr., Dolgas, C.M., Watson, R.E., Jr., Herman, J.P. The C-type natriuretic peptide receptor is the predominant natriuretic peptide receptor mRNA expressed in rat hypothalamus. J. Neuroendocrinol., 1995, 7, 305-309.
21. Lein, E.S., Hawrylycz, M.J., Ao, N., Ayres, M., Bensinger, A., Bernard, A., Boe, A.F., Boguski, M.S., Brockway, K.S., Byrnes, E.J., Chen, L., Chen, T.M., Chin, M.C., Chong, J., Crook, B.E., Czaplinska, A., Dang, C.N., Datta, S., Dee, N.R., Desaki, A.L., Desta, T., Diep, E., Dolbeare, T.A., Donelan, M.J., Dong, H.W., Dougherty, J.G., Duncan, B.J., Ebbert, A.J., Eichele, G., Estin, L.K., Faber, C., Facer, B.A., Fields, R., Fischer, S.R., Fliss, T.P., Frensley, C., Gates, S.N., Glattfelder, K.J., Halverson, K.R., Hart, M.R., Hohmann, J.G., Howell, M.P., Jeung, D.P., Johnson, R.A., Karr, P.T., Kawal, R., Kidney, J.M., Knapik, R.H., Kuan, C.L., Lake, J.H., Laramee, A.R., Larsen, K.D., Lau, C., Lemon, T.A., Liang, A.J., Liu, Y., Luong, L.T., Michaels, J., Morgan, J.J., Morgan, R.J., Mortrud, M.T., Mosqueda, N.F., Ng, L.L., Ng, R., Orta, G.J., Overly, C.C., Pak, T.H., Parry, S.E., Pathak, S.D., Pearson, O.C., Puchalski, R.B., Riley, Z.L., Rockett, H.R., Rowland, S.A., Royall, J.J., Ruiz, M.J., Sarno, N.R., Schaffnit, K., Shapovalova, N.V., Sivisay, T., Slaughterbeck, C.R., Smith, S.C., Smith, K.A., Smith, B.I., Sodt, A.J., Stewart, N.N., Stumpf, K.R., Sunkin, S.M., Sutram, M., Tam, A., Teemer, C.D., Thaller, C., Thompson, C.L., Varnam, L.R., Visel, A., Whitlock, R.M., Wohnoutka, P.E., Wolkey, C.K., Wong, V.Y., Wood, M., Yaylaoglu, M.B., Young, R.C., Youngstrom, B.L., Yuan, X.F., Zhang, B., Zwingman, T.A., Jones, A.R. Genome-wide atlas of gene expression in the adult mouse brain. Nature, 2007, 445, 168 176.
22. Muller, D., Olcese, J., Mukhopadhyay, A.K., Middendorff, R. Guanylyl cyclase-B represents the predominant natriuretic peptide receptor expressed at exceptionally high levels in the pineal gland. Brain Res. Mol. Brain Res., 2000, 75, 321-329.
23. Young, J.M., Waters, H., Dong, C., Fulle, H.J., Liman, E.R. Degeneration of the olfactory guanylyl cyclase D gene during primate evolution. PLoS One, 2007, 2, e884.
24. Pifarre, P., Garcia, A., Mengod, G. Species differences in the localization of soluble guanylyl cyclase subunits in monkey and rat brain. J. Comp. Neurol., 2007, 500, 942-957.
25. Mergia, E., Russwurm, M., Zoidl, G., Koesling, D. Major occurrence of the new alpha2beta1 isoform of NO-sensitive guanylyl cyclase in brain. Cell Signal., 2003, 15, 189-195.
26. Esposito, K., Reierson, G.W., Luo, H.R., Wu, G.S., Licinio, J., Wong, M.L. Phosphodiesterase genes and antidepressant treatment response: a review. Ann. Med., 2009, 41, 177-185.
27. Reneerkens, O.A., Rutten, K., Steinbusch, H.W., Blokland, A., Prickaerts, J. Selective phosphodiesterase inhibitors: a promising target for cognition enhancement. Psychopharmacology (Berl), 2009, 202, 419-443.
28. Ke, H., Wang, H. Crystal structures of phosphodiesterases and implications on substrate specificity and inhibitor selectivity. Curr. Top. Med. Chem., 2007, 7, 391-403.
29. Wang, H.G., Lu, F.M., Jin, I., Udo, H., Kandel, E.R., de Vente, J., Walter, U., Lohmann, S.M., Hawkins, R.D., Antonova, I. Presynaptic and postsynaptic roles of NO, cGK, and RhoA in longlasting potentiation and aggregation of synaptic proteins. Neuron, 2005, 45, 389-403.
30. Zhang, K.Y., Card, G.L., Suzuki, Y., Artis, D.R., Fong, D., Gillette, S., Hsieh, D., Neiman, J., West, B.L., Zhang, C., Milburn, M.V., Kim, S.H., Schlessinger, J., Bollag, G.) A glutamine switch mechanism for nucleotide selectivity by phosphodiesterases. Mol. Cell, 2004, 15, 279-286.
31. Zoraghi, R., Bessay, E.P., Corbin, J.D., Francis, S.H. Structural and functional features in human PDE5A1 regulatory domain that provide for allosteric cGMP binding, dimerization, and regulation. J. Biol. Chem., 2005, 280, 12051-12063.
32. Zhan, C.G., Zheng, F. First computational evidence for a catalytic bridging hydroxide ion in a phosphodiesterase active site. J. Am. Chem. Soc., 2001, 123, 2835-2838.
33. Van Staveren, W.C., Steinbusch, H.W., Markerink-Van Ittersum, M., Repaske, D.R., Goy, M.F., Kotera, J., Omori, K., Beavo, J.A., De Vente, J. mRNA expression patterns of the cGMP-hydrolyzing phosphodiesterases types 2, 5, and 9 during development of the rat brain. J. Comp. Neurol., 2003, 467, 566-580.
34. Jarnaess, E., Tasken, K. Spatiotemporal control of cAMP signalling processes by anchored signalling complexes. Biochem. Soc. Trans., 2007, 35, 931-937.
35. Andreeva, S.G., Dikkes, P., Epstein, P.M., Rosenberg, P.A. Expression of cGMP-specific phosphodiesterase 9A mRNA in the rat brain. J. Neurosci., 2001, 21, 9068-9076.
36. van Staveren, W.C., Glick, J., Markerink-van Ittersum, M., Shimizu, M., Beavo, J.A., Steinbusch, H.W., de Vente, J. Cloning and localization of the cGMP-specific phosphodiesterase type 9 in the rat brain. J. Neurocytol., 2002, 31, 729-741.
37. van Staveren, W.C., Steinbusch, H.W., Markerink-van Ittersum, M., Behrends, S., de Vente, J. Species differences in the localization of cGMP-producing and NO-responsive elements in the mouse and rat hippocampus using cGMP immunocytochemistry. Eur. J. Neurosci., 2004, 19, 2155-2168.
38. Reyes-Irisarri, E., Markerink-Van Ittersum, M., Mengod, G., de Vente, J. Expression of the cGMP-specific phosphodiesterases 2 and 9 in normal and Alzheimer's disease human brains. Eur. J. Neurosci., 2007, 25, 3332-3338.
39. Polli, J.W., Kincaid, R.L. Expression of a calmodulin-dependent phosphodiesterase isoform (PDE1B1) correlates with brain regions having extensive dopaminergic innervation. J. Neurosci., 1994, 14, 1251-1261.
40. Yan, C., Bentley, J.K., Sonnenburg, W.K., Beavo, J.A. Differential expression of the 61 kDa and 63 kDa calmodulin-dependent phosphodiesterases in the mouse brain. J. Neurosci., 1994, 14, 973 984.
41. Yan, C., Zhao, A.Z., Bentley, J.K., Beavo, J.A. The calmodulindependent phosphodiesterase gene PDE1C encodes several functionally different splice variants in a tissue-specific manner. J. Biol. Chem., 1996, 271, 25699-25706.
42. Yu, J., Wolda, S.L., Frazier, A.L., Florio, V.A., Martins, T.J., Snyder, P.B., Harris, E.A., McCaw, K.N., Farrell, C.A., Steiner, B., Bentley, J.K., Beavo, J.A., Ferguson, K., Gelinas, R. Identification and characterisation of a human calmodulin-stimulated phosphodiesterase PDE1B1. Cell Signal., 1997, 9, 519-529.
43. Stephenson, D.T., Coskran, T.M., Wilhelms, M.B., Adamowicz, W.O., O'Donnell, M.M., Muravnick, K.B., Menniti, F.S., Kleiman, R.J., Morton, D. Immunohistochemical localization of phosphodiesterase 2A in multiple mammalian species. J. Histochem. Cytochem., 2009, 57, 933-949.
44. Reinhardt, R.R., Bondy, C.A. Differential cellular pattern of gene expression for two distinct cGMP-inhibited cyclic nucleotide phosphodiesterases in developing and mature rat brain. Neuroscience, 1996, 72, 567-578.
45. Coskran, T.M., Morton, D., Menniti, F.S., Adamowicz, W.O., Kleiman, R.J., Ryan, A.M., Strick, C.A., Schmidt, C.J., Stephenson, D.T. Immunohistochemical localization of phosphodiesterase 10A in multiple mammalian species. J. Histochem. Cytochem., 2006, 54, 1205-1213.
46. Hebb, A.L., Robertson, H.A., Denovan-Wright, E.M. Striatal phosphodiesterase mRNA and protein levels are reduced in Huntington's disease transgenic mice prior to the onset of motor symptoms. Neuroscience, 2004, 123, 967-981.
47. Seeger, T.F., Bartlett, B., Coskran, T.M., Culp, J.S., James, L.C., Krull, D.L., Lanfear, J., Ryan, A.M., Schmidt, C.J., Strick, C.A., Varghese, A.H., Williams, R.D., Wylie, P.G., Menniti, F.S. Immunohistochemical localization of PDE10A in the rat brain. Brain Res., 2003, 985, 113-126.
48. Kruse, L.S., Moller, M., Tibaek, M., Gammeltoft, S., Olesen, J., Kruuse, C. PDE9A, PDE10A, and PDE11A expression in rat trigeminovascular pain signalling system. Brain Res., 2009, 1281, 25-34.
49. Loughney, K., Taylor, J., Florio, V.A. 3', 5'-cyclic nucleotide phosphodiesterase 11A: localization in human tissues. Int. J. Impot. Res., 2005, 17, 320-325.
50. Hofmann, F., Ammendola, A., Schlossmann, J. Rising behind NO: cGMP-dependent protein kinases. J. Cell Sci., 2000, 113 (Pt 10), 1671-1676.
51. Pfeifer, A., Ruth, P., Dostmann, W., Sausbier, M., Klatt, P., Hofmann, F. Structure and function of cGMP-dependent protein kinases. Rev. Physiol. Biochem. Pharmacol., 1999, 135, 105-149.
52. Wang, X., Robinson, P.J. Cyclic GMP-dependent protein kinase and cellular signaling in the nervous system. J. Neurochem., 1997, 68, 443-456.
53. Domek-Lopacinska, K., Strosznajder, J.B. Cyclic GMP metabolism and its role in brain physiology. J. Physiol. Pharmacol., 2005, 56 Suppl 2, 15-34.
54. Houslay, M.D. Compartmentalization of cyclic AMP phosphodiesterases, signalling 'crosstalk', desensitization and the phosphorylation of Gi-2 add cell specific personalization to the control of the levels of the second messenger cyclic AMP. Adv. Enzyme Regul., 1995, 35, 303-338.
55. Conti, M., Beavo, J. Biochemistry and physiology of cyclic nucleotide phosphodiesterases: essential components in cyclic nucleotide signaling. Annu. Rev. Biochem., 2007, 76, 481-511.
56. Corbin, J.D., Turko, I.V., Beasley, A., Francis, S.H. Phosphorylation of phosphodiesterase-5 by cyclic nucleotide-dependent protein kinase alters its catalytic and allosteric cGMP-binding activities. Eur. J. Biochem., 2000, 267, 2760-2767.
57. Zaccolo, M., Movsesian, M.A. cAMP and cGMP signaling crosstalk: role of phosphodiesterases and implications for cardiac pathophysiology. Circ. Res., 2007, 100, 1569-1578.
58. Pelligrino, D.A., Wang, Q. Cyclic nucleotide crosstalk and the regulation of cerebral vasodilation. Prog. Neurobiol., 1998, 56, 1-18.
59. Garthwaite, J. Neuronal nitric oxide synthase and the serotonin transporter get harmonious. Proc. Natl. Acad. Sci. U. S. A., 2007, 104, 7739-7740.
60. Maurice, D.H. Cyclic nucleotide phosphodiesterase-mediated integration of cGMP and cAMP signaling in cells of the cardiovascular system. Front. Biosci., 2005, 10, 1221-1228.
61. Murthy, K.S. Activation of phosphodiesterase 5 and inhibition of guanylate cyclase by cGMP-dependent protein kinase in smooth muscle. Biochem. J., 2001, 360, 199-208.
62. Malenka, R.C., Nicoll, R.A. Learning and memory. Never fear, LTP is hear. Nature, 1997, 390, 552-553.
63. Shors, T.J., Seib, T.B., Levine, S., Thompson, R.F. Inescapable versus escapable shock modulates long-term potentiation in the rat hippocampus. Science, 1989, 244, 224-226.
64. Yang, C.H., Huang, C.C., Hsu, K.S. Behavioral stress modifies hippocampal synaptic plasticity through corticosterone-induced sustained extracellular signal-regulated kinase/mitogen-activated protein kinase activation. J. Neurosci., 2004, 24, 11029-11034.
65. Ahmed, T., Frey, J.U., Korz, V. Long-term effects of brief acute stress on cellular signaling and hippocampal LTP. J. Neurosci., 2006, 26, 3951-3958.
66. Levkovitz, Y., Grisaru, N., Segal, M. Transcranial magnetic stimulation and antidepressive drugs share similar cellular effects in rat hippocampus. Neuropsychopharmacology, 2001, 24, 608-616.
67. Stewart, C.A., Reid, I.C. Repeated ECS and fluoxetine administration have equivalent effects on hippocampal synaptic plasticity. Psychopharmacology (Berl), 2000, 148, 217-223.
68. Dranovsky, A., Hen, R. Hippocampal neurogenesis: regulation by stress and antidepressants. Biol. Psychiatry, 2006, 59, 1136-1143.
69. Duman, R.S. Depression: a case of neuronal life and death? Biol. Psychiatry, 2004, 56, 140-145.
70. Sheline, Y.I., Wang, P.W., Gado, M.H., Csernansky, J.G., Vannier, M.W. Hippocampal atrophy in recurrent major depression. Proc. Natl. Acad. Sci. U. S. A., 1996, 93, 3908-3913.
71. MacQueen, G.M., Campbell, S., McEwen, B.S., Macdonald, K., Amano, S., Joffe, R.T., Nahmias, C., Young, L.T. Course of illness, hippocampal function, and hippocampal volume in major depression. Proc. Natl. Acad. Sci. U. S. A., 2003, 100, 1387-1392.
72. Warner-Schmidt, J.L., Duman, R.S. Hippocampal neurogenesis: opposing effects of stress and antidepressant treatment. Hippocampus, 2006, 16, 239-249.
73. Nakagawa, S., Kim, J.E., Lee, R., Malberg, J.E., Chen, J., Steffen, C., Zhang, Y.J., Nestler, E.J., Duman, R.S. Regulation of neurogenesis in adult mouse hippocampus by cAMP and the cAMP response element-binding protein. J. Neurosci., 2002, 22, 3673-3682.
74. Malberg, J.E., Eisch, A.J., Nestler, E.J., Duman, R.S. Chronic antidepressant treatment increases neurogenesis in adult rat hippocampus. J. Neurosci., 2000, 20, 9104-9110.
75. Neitz, A., Mergia, E., Eysel, U.T., Koesling, D., Mittmann, T. Presynaptic nitric oxide/cGMP facilitates glutamate release via hyperpolarization-activated cyclic nucleotide-gated channels in the hippocampus. Eur. J. Neurosci., 2011, 33, 1611-1621.
76. Wang, H., Robinson, H., Ke, H. The molecular basis for different recognition of substrates by phosphodiesterase families 4 and 10. J. Mol. Biol., 2007, 371, 302-307.
77. Serulle, Y., Arancio, O., Ziff, E.B. A role for cGMP-dependent protein kinase II in AMPA receptor trafficking and synaptic plasticity. Channels (Austin), 2008, 2, 230-232.
78. Serulle, Y., Zhang, S., Ninan, I., Puzzo, D., McCarthy, M., Khatri, L., Arancio, O., Ziff, E.B. A GluR1-cGKII interaction regulates AMPA receptor trafficking. Neuron, 2007, 56, 670-688.
79. Chen, Y., Zhuang, S., Cassenaer, S., Casteel, D.E., Gudi, T., Boss, G.R., Pilz, R.B. Synergism between calcium and cyclic GMP in cyclic AMP response element-dependent transcriptional regulation requires cooperation between CREB and C/EBP-beta. Mol. Cell Biol., 2003, 23, 4066-4082.
80. Lu, Y.F., Kandel, E.R., Hawkins, R.D. Nitric oxide signaling contributes to late-phase LTP and CREB phosphorylation in the hippocampus. J. Neurosci., 1999, 19, 10250-10261.
81. Lu, Y.F., Hawkins, R.D. Ryanodine receptors contribute to cGMPinduced late-phase LTP and CREB phosphorylation in the hippocampus. J. Neurophysiol., 2002, 88, 1270-1278.
82. Zhang, R., Wang, Y., Zhang, L., Zhang, Z., Tsang, W., Lu, M., Chopp, M. Sildenafil (Viagra) induces neurogenesis and promotes functional recovery after stroke in rats. Stroke, 2002, 33, 2675 2680.
83. Zhang, R., Zhang, L., Zhang, Z., Wang, Y., Lu, M., Lapointe, M., Chopp, M. A nitric oxide donor induces neurogenesis and reduces functional deficits after stroke in rats. Ann. Neurol., 2001, 50, 602-611.
84. Wang, L., Gang Zhang, Z., Lan Zhang, R., Chopp, M. Activation of the PI3-K/Akt pathway mediates cGMP enhanced-neurogenesis in the adult progenitor cells derived from the subventricular zone. J. Cereb. Blood Flow Metab., 2005, 25, 1150-1158.
85. Tojima, T., Itofusa, R., Kamiguchi, H. The nitric oxide-cGMP pathway controls the directional polarity of growth cone guidance via modulating cytosolic Ca2+ signals. J. Neurosci., 2009, 29, 7886-7897.
86. Nishiyama, M., Hoshino, A., Tsai, L., Henley, J.R., Goshima, Y., Tessier-Lavigne, M., Poo, M.M., Hong, K. Cyclic AMP/GMPdependent modulation of Ca2+ channels sets the polarity of nerve growth-cone turning. Nature, 2003, 423, 990-995.
87. Murray, A.J., Tucker, S.J., Shewan, D.A. cAMP-dependent axon guidance is distinctly regulated by Epac and protein kinase A. J. Neurosci., 2009, 29, 15434-15444.
88. Shelly, M., Lim, B.K., Cancedda, L., Heilshorn, S.C., Gao, H., Poo, M.M. Local and long-range reciprocal regulation of cAMP and cGMP in axon/dendrite formation. Science, 2010, 327, 547-552.
89. Zhu, C.B., Hewlett, W.A., Feoktistov, I., Biaggioni, I., Blakely, R.D. Adenosine receptor, protein kinase G, and p38 mitogenactivated protein kinase-dependent up-regulation of serotonin transporters involves both transporter trafficking and activation. Mol. Pharmacol., 2004, 65, 1462-1474.
90. Chanrion, B., Mannoury la Cour, C., Bertaso, F., Lerner-Natoli, M., Freissmuth, M., Millan, M.J., Bockaert, J., Marin, P. Physical interaction between the serotonin transporter and neuronal nitric oxide synthase underlies reciprocal modulation of their activity. Proc. Natl. Acad. Sci. U. S. A., 2007, 104, 8119-8124.
91. Shinkai, T., Ohmori, O., Hori, H., Nakamura, J. Allelic association of the neuronal nitric oxide synthase (NOS1) gene with schizophrenia. Mol. Psychiatry, 2002, 7, 560-563.
92. Okumura, T., Kishi, T., Okochi, T., Ikeda, M., Kitajima, T., Yamanouchi, Y., Kinoshita, Y., Kawashima, K., Tsunoka, T., Inada, T., Ozaki, N., Iwata, N. Genetic association analysis of functional polymorphisms in neuronal nitric oxide synthase 1 gene (NOS1) and mood disorders and fluvoxamine response in major depressive disorder in the Japanese population. Neuropsychobiology, 2010, 61, 57-63.
93. Wong, M.L., Whelan, F., Deloukas, P., Whittaker, P., Delgado, M., Cantor, R.M., McCann, S.M., Licinio, J. Phosphodiesterase genes are associated with susceptibility to major depression and antidepressant treatment response. Proc. Natl. Acad. Sci. U. S. A., 2006, 103, 15124-15129.
94. Teranishi, K.S., Slager, S.L., Garriock, H., Kraft, J.B., Peters, E.J., Reinalda, M.S., Jenkins, G.D., McGrath, P.J., Hamilton, S.P. Variants in PDE11A and PDE1A are not associated with citalopram response. Mol. Psychiatry, 2007, 12, 1061-1063.
95. Cabanero, M., Laje, G., Detera-Wadleigh, S., McMahon, F.J. Association study of phosphodiesterase genes in the Sequenced Treatment Alternatives to Relieve Depression sample. Pharmacogenet. Genom., 2009, 19, 235-238.
96. Fatemi, S.H., Folsom, T.D., Reutiman, T.J., Vazquez, G. Phosphodiesterase signaling system is disrupted in the cerebella of subjects with schizophrenia, bipolar disorder, and major depression. Schizophr. Res., 2010, 119, 266-267.
97. Zhang, J., Huang, X.Y., Ye, M.L., Luo, C.X., Wu, H.Y., Hu, Y., Zhou, Q.G., Wu, D.L., Zhu, L.J., Zhu, D.Y. Neuronal nitric oxide synthase alteration accounts for the role of 5-HT1A receptor in modulating anxiety-related behaviors. J. Neurosci., 2010, 30, 2433-2441.
98. Chiavegatto, S., Dawson, V.L., Mamounas, L.A., Koliatsos, V.E., Dawson, T.M., Nelson, R.J. Brain serotonin dysfunction accounts for aggression in male mice lacking neuronal nitric oxide synthase. Proc. Natl. Acad. Sci. U. S. A., 2001, 98, 1277-1281.
99. Balda, M.A., Anderson, K.L., Itzhak, Y. Development and persistence of long-lasting behavioral sensitization to cocaine in female mice: role of the nNOS gene. Neuropharmacology, 2009, 56, 709-715.
100. Boettger, M.K., Uceyler, N., Zelenka, M., Schmitt, A., Reif, A., Chen, Y., Sommer, C. Differences in inflammatory pain in nNOS-, iNOS and eNOS-deficient mice. Eur. J. Pain, 2007, 11, 810-818.
101. Juch, M., Smalla, K.H., Kahne, T., Lubec, G., Tischmeyer, W., Gundelfinger, E.D., Engelmann, M. Congenital lack of nNOS impairs long-term social recognition memory and alters the olfactory bulb proteome. Neurobiol. Learn Mem., 2009, 92, 469-484.
102. Haghikia, A., Mergia, E., Friebe, A., Eysel, U.T., Koesling, D., Mittmann, T. Long-term potentiation in the visual cortex requires both nitric oxide receptor guanylyl cyclases. J. Neurosci., 2007, 27, 818-823.
103. Siuciak, J.A., McCarthy, S.A., Chapin, D.S., Reed, T.M., Vorhees, C.V., Repaske, D.R. Behavioral and neurochemical characterization of mice deficient in the phosphodiesterase-1B (PDE1B) enzyme. Neuropharmacology, 2007, 53, 113-124.
104. Reed, T.M., Repaske, D.R., Snyder, G.L., Greengard, P., Vorhees, C.V. Phosphodiesterase 1B knock-out mice exhibit exaggerated locomotor hyperactivity and DARPP-32 phosphorylation in response to dopamine agonists and display impaired spatial learning. J. Neurosci., 2002, 22, 5188-5197.
105. Ehrman, L.A., Williams, M.T., Schaefer, T.L., Gudelsky, G.A., Reed, T.M., Fienberg, A.A., Greengard, P., Vorhees, C.V. Phosphodiesterase 1B differentially modulates the effects of methamphetamine on locomotor activity and spatial learning through DARPP32-dependent pathways: evidence from PDE1BDARPP32 double-knockout mice. Genes Brain Behav., 2006, 5, 540-551.
106. Siuciak, J.A., McCarthy, S.A., Chapin, D.S., Martin, A.N., Harms, J.F., Schmidt, C.J. Behavioral characterization of mice deficient in the phosphodiesterase-10A (PDE10A) enzyme on a C57/Bl6N congenic background. Neuropharmacology, 2008, 54, 417-427.
107. Siuciak, J.A., McCarthy, S.A., Chapin, D.S., Fujiwara, R.A., James, L.C., Williams, R.D., Stock, J.L., McNeish, J.D., Strick, C.A., Menniti, F.S., Schmidt, C.J. Genetic deletion of the striatumenriched phosphodiesterase PDE10A: evidence for altered striatal function. Neuropharmacology, 2006, 51, 374-385.
108. Werner, C., Raivich, G., Cowen, M., Strekalova, T., Sillaber, I., Buters, J.T., Spanagel, R., Hofmann, F. Importance of NO/cGMP signalling via cGMP-dependent protein kinase II for controlling emotionality and neurobehavioural effects of alcohol. Eur. J. Neurosci., 2004, 20, 3498-3506.
109. Joca, S.R., Guimaraes, F.S. Inhibition of neuronal nitric oxide synthase in the rat hippocampus induces antidepressant-like effects. Psychopharmacology (Berl), 2006, 185, 298-305.
110. Ulak, G., Mutlu, O., Akar, F.Y., Komsuoglu, F.I., Tanyeri, P., Erden, B.F. Neuronal NOS inhibitor 1-(2-trifluoromethylphenyl) imidazole augment the effects of antidepressants acting via serotonergic system in the forced swimming test in rats. Pharmacol. Biochem. Behav., 2008, 90, 563-568.
111. Zhou, Q.G., Hu, Y., Hua, Y., Hu, M., Luo, C.X., Han, X., Zhu, X.J., Wang, B., Xu, J.S., Zhu, D.Y. Neuronal nitric oxide synthase contributes to chronic stress-induced depression by suppressing hippocampal neurogenesis. J. Neurochem., 2007, 103, 1843-1854.
112. Khovryakov, A.V., Podrezova, E.P., Kruglyakov, P.P., Shikhanov, N.P., Balykova, M.N., Semibratova, N.V., Sosunov, A.A., McKhann, G., 2nd, Airapetyants, M.G. Involvement of the NO synthase system in stress-mediated brain reactions. Neurosci. Behav. Physiol., 2010, 40, 333-337.
113. Volke, V., Wegener, G., Vasar, E. Augmentation of the NO-cGMP cascade induces anxiogenic-like effect in mice. J. Physiol. Pharmacol., 2003, 54, 653-660.
114. Hotchkiss, A.K., Pyter, L.M., Gatien, M.L., Wen, J.C., Milman, H.A., Nelson, R.J. Aggressive behavior increases after termination of chronic sildenafil treatment in mice. Physiol. Behav., 2005, 83, 683-688.
115. Kaster, M.P., Rosa, A.O., Santos, A.R., Rodrigues, A.L. Involvement of nitric oxide-cGMP pathway in the antidepressantlike effects of adenosine in the forced swimming test. Int. J. Neuropsychopharmacol., 2005, 8, 601-606.
116. Dhir, A., Kulkarni, S.K. Involvement of nitric oxide (NO) signaling pathway in the antidepressant action of bupropion, a dopamine reuptake inhibitor. Eur. J. Pharmacol., 2007, 568, 177-185.
117. Brink, C.B., Clapton, J.D., Eagar, B.E., Harvey, B.H. Appearance of antidepressant-like effect by sildenafil in rats after central muscarinic receptor blockade: evidence from behavioural and neuro-receptor studies. J. Neural. Transm., 2008, 115, 117-125.
118. Masood, A., Huang, Y., Hajjhussein, H., Xiao, L., Li, H., Wang, W., Hamza, A., Zhan, C.G., O'Donnell, J.M. Anxiolytic effects of phosphodiesterase-2 inhibitors associated with increased cGMP signaling. J. Pharmacol. Exp. Ther., 2009, 331, 690-699.
119. Masood, A., Nadeem, A., Mustafa, S.J., O'Donnell, J.M. Reversal of oxidative stress-induced anxiety by inhibition of phosphodiesterase-2 in mice. J. Pharmacol. Exp. Ther., 2008, 326, 369-379.
120. Miller, M.R., Megson, I.L. Recent developments in nitric oxide donor drugs. Br. J. Pharmacol., 2007, 151, 305-321.
121. Belik, J. Riociguat, an oral soluble guanylate cyclase stimulator for the treatment of pulmonary hypertension. Curr. Opin. Investig. Drugs, 2009, 10, 971-979.
122. Mitrovic, V., Hernandez, A.F., Meyer, M., Gheorghiade, M. Role of guanylate cyclase modulators in decompensated heart failure. Heart Fail. Rev., 2009, 14, 309-319.
123. Lugnier, C. Cyclic nucleotide phosphodiesterase (PDE) superfamily: a new target for the development of specific therapeutic agents. Pharmacol. Ther., 2006, 109, 366-398.
124. Bender, A.T., Beavo, J.A. Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use. Pharmacol. Rev., 2006, 58, 488-520.
125. Spencer, C.M., Brogden, R.N. Anagrelide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the treatment of thrombocythaemia. Drugs, 1994, 47, 809-822.
126. Kambayashi, J., Liu, Y., Sun, B., Shakur, Y., Yoshitake, M., Czerwiec, F. Cilostazol as a unique antithrombotic agent. Curr. Pharm. Des., 2003, 9, 2289-2302.
127. Sharma, M., Teerlink, J.R. A rational approach for the treatment of acute heart failure: current strategies and future options. Curr. Opin. Cardiol., 2004, 19, 254-263.
128. Chen, R.W., Williams, A.J., Liao, Z., Yao, C., Tortella, F.C., Dave, J.R. Broad spectrum neuroprotection profile of phosphodiesterase inhibitors as related to modulation of cell-cycle elements and caspase-3 activation. Neurosci. Lett., 2007, 418, 165-169.
129. Goldenberg, M.M. Safety and efficacy of sildenafil citrate in the treatment of male erectile dysfunction. Clin. Ther., 1998, 20, 1033 1048.
130. Paul, I.A., Skolnick, P. Glutamate and depression: clinical and preclinical studies. Ann. N. Y. Acad. Sci., 2003, 1003, 250-272.